Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Inflammatory bowel disease (IBD) encompasses a group of inflammatory conditions such as Crohn’s and ulcerative colitis, which currently affect about 1% of the population in the UK, Europe and North America. It is an illness that happens behind closed doors, but the impact for the patient and their family and friends is often harrowing. Prof Simon Travis, a leading consultant at the Nuffield Department of Medicine, is interviewed about IBD.

Similar stories

Immune response may be harnessed to control HIV

Researchers have unveiled primary trial results that show encouraging advances in HIV treatment driven by immune-based therapies. New antibody therapies could offer alternative to current treatments.

Oxford and GSK launch £50m programme to advance cancer research

Global biopharma company GSK invests up to £50 million in a collaboration with Oxford to advance the understanding of how cancer develops, which could inform future development of vaccines to prevent cancer.

Fitness compensation in m.tuberculosis: a game of genetic chess

Viktoria Brunner takes us behind the scenes of their latest publication 'Compensatory mutations are associated with increased in vitro growth in resistant clinical samples of Mycobacterium tuberculosis' published in Microbial Genomics.

Emerging Leaders Prize recognises future leaders in hepatitis research

Three outstanding hepatitis researchers have been announced today as winners of the Medical Research Foundation’s seventh Emerging Leaders Prize.

Similar stories

Immune response may be harnessed to control HIV

Researchers have unveiled primary trial results that show encouraging advances in HIV treatment driven by immune-based therapies. New antibody therapies could offer alternative to current treatments.

Oxford and GSK launch £50m programme to advance cancer research

Global biopharma company GSK invests up to £50 million in a collaboration with Oxford to advance the understanding of how cancer develops, which could inform future development of vaccines to prevent cancer.

Fitness compensation in m.tuberculosis: a game of genetic chess

Viktoria Brunner takes us behind the scenes of their latest publication 'Compensatory mutations are associated with increased in vitro growth in resistant clinical samples of Mycobacterium tuberculosis' published in Microbial Genomics.

Emerging Leaders Prize recognises future leaders in hepatitis research

Three outstanding hepatitis researchers have been announced today as winners of the Medical Research Foundation’s seventh Emerging Leaders Prize.